Skip to Content

INCY 20 (Jakafi 20 mg)

Generic Name: ruxolitinib

Pill imprint INCY 20 has been identified as Jakafi 20 mg.

Jakafi is used in the treatment of myelofibrosis; myeloproliferative disorders; polycythemia vera and belongs to the drug class multikinase inhibitors. Risk cannot be ruled out during pregnancy. Jakafi 20 mg is not a controlled substance under the Controlled Substance Act (CSA).

Jakafi 20 mg INCY 20
Discount Card Promo
Jakafi
Generic Name:
ruxolitinib
Imprint:
INCY 20
Strength:
20 mg
Color:
White
Shape:
Capsule-shape
Availability:
Prescription only
Drug Class:
Multikinase inhibitors
Pregnancy Category:
C - Risk cannot be ruled out
CSA Schedule:
Not a controlled drug
Manufacturer:
Incyte Corporation
National Drug Code (NDC):
50881-0020
Inactive Ingredients:
microcrystalline cellulose
lactose monohydrate
silicon dioxide
hydroxypropyl cellulose
povidone
sodium starch glycolate type A potato
magnesium stearate

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide